|View printer-friendly version|
|May 28, 2006 1:47 p.m.|
|Teva Announces Tentative Approval for Generic Cozaar® Tablets|
Jerusalem, Israel, May 28, 2006 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Merck's antihypertensive agent Cozaar® (Losartan Potassium) Tablets, 25 mg, 50 mg and 100 mg. Final approval of this ANDA is expected in April 2010 when patent protection for the brand product expires.